Hostname: page-component-8448b6f56d-xtgtn Total loading time: 0 Render date: 2024-04-19T01:07:24.989Z Has data issue: false hasContentIssue false
  • English
  • Français

Patients' Knowledge of Key Messaging in Drug Safety Communications for Zolpidem and Eszopiclone: A National Survey

Published online by Cambridge University Press:  01 January 2021

Aaron S. Kesselheim ,
Michael S. Sinha ,
Paula Rausch ,
Zhigang Lu ,
Frazer A. Tessema ,
Brian M. Lappin ,
Esther H. Zhou ,
Gerald J. Dal Pan ,
Lee Zwanziger  and
Amy Ramanadham
...Show all authors
Get access Rights & Permissions [Opens in a new window]

Abstract

Drug Safety Communications (DSCs) are used by the Food and Drug Administration (FDA) to inform health care providers, patients, caregivers, and the general public about safety issues related to FDA-approved drugs. To assess patient knowledge of the messaging contained in DSCs related to the sleep aids zolpidem and eszopiclone, we conducted a large, cross-sectional patient survey of 1,982 commercially insured patients selected by stratified random sampling from the Optum Research Database who had filled at least two prescriptions for either zolpidem or eszopiclone between July 1, 2012 and June 30, 2013. Among the 594 respondents (32.7% response rate), two-thirds reported hearing generally about drug safety information prior to starting a new drug, with the remaining one-third “rarely” or “never” hearing such information. Providers and pharmacists were primary sources of drug safety information. Two-thirds of zolpidem users and half of eszopiclone users reported having heard about the related DSC messages, ability to accurately identify the major factual messages was limited (overall median 2 correct out of 5, with men and those reporting higher educational level scoring higher [2/5 vs. 1/5, p=0.001]). Respondents reacted to new drug safety information about their sleep aids by reporting that they would want to learn about alternative ways to help them sleep (70%) and seek out more information about the safety of their specific sleeping pill (59-78%). Opportunities may exist for the FDA to work with providers and pharmacies to help ensure the DSC information is more widely received and is more fully understood by those taking the affected medications.

Type
Independent Articles
Information
Journal of Law, Medicine & Ethics , Volume 47 , Issue 3: Biomarker Research and Validation: Current Challenges, Future Opportunities , Fall 2019 , pp. 430 - 441
Copyright
Copyright © American Society of Law, Medicine and Ethics 2019

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

U.S. Food and Drug Administration, Drug Safety Communications, available at <http://www.fda.gov/Drugs/DrugSafety/ucm199082.htm> (last visited August 1, 2019).+(last+visited+August+1,+2019).>Google Scholar
Sinha, M. S., Freifeld, C. C., Brownstein, J. S., Donneyong, M. M., Rausch, P., Lappin, B. M., Zhou, E. H., Dal Pan, G.J., Pawar, A. M., Hwang, T. J., Avorn, J., and Kesselheim, A. S., “Social Media Impact of the Food and Drug Administration's Drug Safety Communication Messaging about Zolpidem: Mixed-Methods Analysis,” JMIR: Public Health Surveillance 4, no. 1 (2018): e1, doi: http://dx.doi.org/10.2196/publichealth.7823; Woloshin, S., Schwartz, L. M., Dejene, S. Z., Rausch, P., Dal Pan, G.J., and Kesselheim, A. S., “Media Coverage of FDA Drug Safety Communications about Zolpidem: A Quantitative and Qualitative Analysis,” Journal of Health Communication 22, no. 5 (2017): 365-372.Google Scholar
Food and Drug Administration, Drug Safety Communications, Feb. 25 2019, available at <http://www.fda.gov/Drugs/Drug-Safety/ucm199082.htm> (last visited August 1, 2019).+(last+visited+August+1,+2019).>Google Scholar
Valiyeva, E., Herrmann, N., Rochon, P. A., Gill, S. S., and Anderson, G. M., “Effect of Regulatory Warnings on Antipsychotic Prescription Rates Among Elderly Patients with Dementia: A Population-Based Time-Series Analysis,” CMAJ 179, no. 5 (2008): 438–446.CrossRefGoogle Scholar
Wax, D., Doshi, A., Hossain, S., Bodian, C. A., Krol, M., and Reich, D. L., “Changing Patterns of Postoperative Nausea and Vomiting Prophylaxis Drug use in an Academic Anesthesia Practice,” Journal of Clinical Anesthesia 19, no. 5 (2007): 356–359; Cohen, A., Rabbani, A., Shah, N., et al., “Changes in Glitazone use Among Office-Based Physicians in the U.S., 2003–2009,” Diabetes Care 33 (2010): 823–825.CrossRefGoogle Scholar
Kesselheim, A. S., Donneyong, M., Dal Pan, G.J., Zhou, E. H., Avorn, J., Schneeweiss, S., and Seeger, J. D., “Changes in Prescribing and Healthcare Resource Utilization after FDA Drug Safety Communications Involving Zolpidem-Containing Medications,” Pharmacoepidemiology and Drug Safety 26, no. 6 (2017): 712-721.CrossRefGoogle Scholar
U. S. Food and Drug Administration, “Drug Safety Communication: FDA Approves New Label Changes and Dosing for Zolpidem Products and a Recommendation to Avoid Driving the Day after Using Ambien CR,” May 14, 2013, available at <http://www.fda.gov/Drugs/DrugSafety/ucm352085.htm> (last visited August 1, 2019); U.S. Food and Drug Administration, “Drug Safety Communication: Risk of Next Morning Impairment after use of Insomnia Drugs; FDA Requires Lower Recommended Doses for Certain Drugs Containing Zolpidem (Ambien, Ambien CR, Edluar, and Zolpimist),” January 10, 2013, available at <http://www.fda.gov/Drugs/DrugSafety/ucm334033.htm> (last visited August 1, 2019).+(last+visited+August+1,+2019);+U.S.+Food+and+Drug+Administration,+“Drug+Safety+Communication:+Risk+of+Next+Morning+Impairment+after+use+of+Insomnia+Drugs;+FDA+Requires+Lower+Recommended+Doses+for+Certain+Drugs+Containing+Zolpidem+(Ambien,+Ambien+CR,+Edluar,+and+Zolpimist),”+January+10,+2013,+available+at++(last+visited+August+1,+2019).>Google Scholar
U. S. Food and Drug Administration, FDA Drug Safety Communication: FDA Warns of Next-Day Impairment with Sleep Aid Lunesta (Eszopiclone) and Lowers Recommended Dose,” available at <https://www.fda.gov/Drugs/DrugSafety/ucm397260.htm> (last visited August 1, 2019).+(last+visited+August+1,+2019).>Google Scholar
Sinha, M. S., Freifeld, C. C., Brownstein, J. S., Donneyong, M. M., Rausch, P., Lappin, B. M., Zhou, E. H., Dal Pan, G.J., Pawar, A. M., Hwang, T. J., Avorn, J., and Kesselheim, A. S., “Social Media Impact of the Food and Drug Administration's Drug Safety Communication Messaging about Zolpidem: Mixed-Methods Analysis,” JMIR: Public Health Surveillance 4, no. 1 (2018): e1.Google Scholar
Woloshin, S., Schwartz, L. M., Dejene, S., Rausch, P., Dal Pan, G.J., Zhou, E. H., and Kesselheim, A. S., “Media Coverage of FDA Drug Safety Communications about Zolpidem: A Quantitative and Qualitative Analysis,” Journal of Health Communication 22, no. 5 (2017): 365-372.CrossRefGoogle Scholar
Kesselheim, A. S., Campbell, E. G., Schneeweiss, S., Rausch, P., Lappin, B. M., Zhou, E. H., Seeger, J. D., Brownstein, J. S., Woloshin, S., Schwartz, L. M., Toomey, T., Dal Pan, G.J., and Avorn, J., “Methodological Approaches to Evaluate the Impact of FDA Drug Safety Communications,” Drug Safety 38, no. 6 (2015): 565-575.Google Scholar
Supplementary material: PDF

Kesselheim et al. supplementary material

Kesselheim et al. supplementary material

Download Kesselheim et al. supplementary material(PDF)
PDF 1 MB